There was no significant difference in the inhibitory effect of saracatinib on major intracellular phophosites in CD14+ monocytes and DCs from patients with CEA or CAD (Supplementary Fig. 5b), suggesting that saracatinib is equally effective regardless of the vascular site affected by atherosclerotic disease. Here, CD14 is linked to coronary artery disorder.